• 0 Posts
  • 76 Comments
Joined 7 months ago
cake
Cake day: February 15th, 2026

help-circle








  • I programmed pretty intensively in OCaml a couple years ago to get a better understanding of the language.

    It is a fine language, perfectly suited for general purpose programming, and is in general decently ergonomic. I personally won’t use it as my perfered language though. I find the functor/module system way too powerful, and can easily cause confusion in complex settings. There really is no better system for adhoc polymorphism than type classes. But people standby modules though.

    I feel the good part of OCaml are generally avaliable in most good programming language, thus I kind of feel that the share for OCaml might slowly getting eaten by Rust, but we will see.





  • At times during the conversation, Linda became overwhelmed and turned away from the camera, as Jason pressed on. They recalled that when Mei’s birthday came around earlier this year, they said nothing to each other, though they both assumed it was on the other’s mind.

    “We do not discuss that,” Linda said.

    During the call, Linda finally told her husband how she had spent that day. While he was at work, she finally returned to the old apartment and sat down on Mei’s bed surrounded by all her things. She had purchased a chocolate cupcake on the way and now picked at it as she imagined that her daughter was still at her side.

    By the time she finished telling her story, Jason was welling up. Linda glanced over at him tenderly. “My husband didn’t know this,” she said. “I cannot cry every day, but that day, I think, I can cry in the room.”

    Oh man…


  • Turns out they did on both mice and primates, and the side effect is also evaluated:

    Another potential concern, however, emerged about 1 month before Mei was treated: the final conclusions of a primate toxicology study conducted at PriMed. The company’s report, dated 17 February 2025, concluded all four monkeys that received the therapy, whether at low or high doses, developed moderate to severe liver damage.

    However, the ethics board did not review the safety report:

    An ethics panel at Xinhua Hospital in China approved a gene-editing trial, but had not reviewed primate data suggesting safety concerns. Another hospital panel later concluded the experimental treatment was “definitely related” to Mei’s death.

    Even worse, the brain development data from the primate study is entirely unconvincing:

    But four of the experts Science asked to assess this figure, including one of the original reviewers of the Nature manuscript, expressed concerns about how well the primate proof-of-concept study was conducted. The submitted paper had no control samples to show the stain was selectively highlighting the gene editor. “It’s completely unconvincing,” says David Sanders, a biochemist at Purdue University who has studied gene therapy. “One can’t have the confidence that one isn’t mostly looking at background staining.”